Endothelial MLKL Inhibition Reduces Hyperoxia‐Induced Bronchopulmonary Dysplasia in Neonatal Mice
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Junjie Ning und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hyperoxia, Bronchopulmonary Dysplasia, Protein Kinases, Endothelial Cells. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Bronchopulmonary dysplasia (BPD) remains a severe complication in premature infants requiring prolonged oxygen therapy, with vascular endothelial dysfunction recognised as a critical contributor to disease progression. Mixed lineage kinase domain‐like protein ( MLKL )‐mediated necroptosis, an essential form of regulated cell death implicated in various pulmonary disorders, has not been fully investigated in the context of BPD. Here, we utilised a neonatal mouse model of hyperoxia exposure to elucidate the role and mechanisms of MLKL ‐mediated necroptosis in BPD pathogenesis. Our analysis demonstrated morphological characteristics of necroptosis in pulmonary vascular endothelial cells (ECs) under hyperoxic conditions, accompanied by significant elevation of MLKL protein levels and marked upregulation of MLKL gene expression specifically in vascular ECs. Administration of the MLKL inhibitor necrosulfonamide (NSA), either immediately postnatally or at postnatal day 7, effectively mitigated lung injury, preserved alveolar structure and partially restored pulmonary vascular growth. Moreover, MLKL conditional knockout in ECs significantly attenuated both structural and functional pulmonary abnormalities induced by hyperoxia. Collectively, our findings indicate that MLKL ‐mediated necroptosis in vascular ECs plays a pivotal role in hyperoxia‐induced BPD. Therapeutically targeting MLKL to maintain endothelial integrity presents a promising approach to prevent or alleviate BPD in premature infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.
- Department of Pediatrics, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, China.
ORCID-Profile: Junjie Ning, Lina Qiao
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Ning, J., Deng, J., Sang, Y., & Qiao, L. (2026). Endothelial MLKL Inhibition Reduces Hyperoxia‐Induced Bronchopulmonary Dysplasia in Neonatal Mice. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71035
Vancouver
Ning J, Deng J, Sang Y, Qiao L. Endothelial MLKL Inhibition Reduces Hyperoxia‐Induced Bronchopulmonary Dysplasia in Neonatal Mice. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71035
BibTeX
@article{Ning2026,
author = {Ning, Junjie and Deng, Junchao and Sang, Yating and Qiao, Lina},
title = {Endothelial MLKL Inhibition Reduces Hyperoxia‐Induced Bronchopulmonary Dysplasia in Neonatal Mice},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71035}
}
EUVIMED